1. Home
  2. CHD vs INCY Comparison

CHD vs INCY Comparison

Compare CHD & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Church & Dwight Company Inc.

CHD

Church & Dwight Company Inc.

HOLD

Current Price

$92.05

Market Cap

19.8B

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$102.63

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHD
INCY
Founded
1846
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.8B
17.0B
IPO Year
N/A
1993

Fundamental Metrics

Financial Performance
Metric
CHD
INCY
Price
$92.05
$102.63
Analyst Decision
Buy
Buy
Analyst Count
18
21
Target Price
$100.39
$96.79
AVG Volume (30 Days)
2.1M
2.1M
Earning Date
01-30-2026
02-09-2026
Dividend Yield
1.30%
N/A
EPS Growth
42.14
3878.02
EPS
3.17
5.90
Revenue
$6,141,000,000.00
$4,813,105,000.00
Revenue This Year
$2.50
$19.59
Revenue Next Year
$3.34
$10.80
P/E Ratio
$28.59
$17.99
Revenue Growth
1.45
18.09
52 Week Low
$81.33
$53.56
52 Week High
$116.46
$112.29

Technical Indicators

Market Signals
Indicator
CHD
INCY
Relative Strength Index (RSI) 71.47 49.58
Support Level $83.52 $102.68
Resistance Level $86.49 $108.58
Average True Range (ATR) 1.93 3.55
MACD 0.78 -0.03
Stochastic Oscillator 94.91 32.54

Price Performance

Historical Comparison
CHD
INCY

About CHD Church & Dwight Company Inc.

Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which, together with Arm & Hammer, account for around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: